Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Gates Foundation invests $40 million in UK immunotherapy company

share with twitter share with LinkedIn share with facebook
09/18/2017 | 02:59am EDT
FILE PHOTO: Melinda Gates and her husband attend a news conference in New York

LONDON (Reuters) - The Bill & Melinda Gates Foundation is to invest up to $40 million (29.41 million pounds) in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.

Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it has collaborations with Roche (>> Roche Holding Ltd.), GlaxoSmithKline (>> GlaxoSmithKline), AstraZeneca (>> AstraZeneca) and Eli Lilly (>> Eli Lilly and Company).

The tie-up with the Gates Foundation will extend the work into finding and developing new treatments for tuberculosis, HIV and other infectious diseases.

(Reporting by Ben Hirschler; Editing by Mark Potter)

share with twitter share with LinkedIn share with facebook
Latest news on ASTRAZENECA PLC
08:58aASTRAZENECA : Granted Fast Track Designation for Farxiga
DJ
08:13aASTRAZENECA : FARXIGA Granted Fast Track Designation in the US for Heart Failure..
BU
07:41aASTRAZENECA : Goldman Sachs reiterates its Sell rating
MD
07:03aASTRAZENECA : BRILINTA Significantly Reduced the Rate of the Composite of Stroke..
BU
06:21aJ&J raises forecast after quarterly profit beats estimates
RE
06:16aJ&J raises forecast after quarterly profit beats estimates
RE
03:44aRussia to mass produce experimental COVID-19 vaccine - wealth fund head
RE
02:06aASTRAZENECA : Brilinta significantly reduced the rate of the composite of stroke..
PU
07/15Health Care Up As Moderna, AstraZeneca Rise On Vaccine Optimism -- Health Car..
DJ
07/15ASTRAZENECA : Early-stage trial data on AstraZeneca COVID-19 vaccine due July 20..
RE
More news
Financials (USD)
Sales 2020 26 814 M - -
Net income 2020 3 159 M - -
Net Debt 2020 12 648 M - -
P/E ratio 2020 49,5x
Yield 2020 2,48%
Capitalization 149 B 149 B -
EV / Sales 2019
EV / Sales 2020 6,01x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 112,00 $
Last Close Price 113,25 $
Spread / Highest target 28,5%
Spread / Average Target -1,10%
Spread / Lowest Target -33,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC18.26%148 785
JOHNSON & JOHNSON1.64%390 605
ROCHE HOLDING AG8.01%305 807
MERCK & CO., INC.-12.66%200 515
PFIZER, INC.-10.08%198 419
NOVARTIS AG-9.65%193 847